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Résumé en
anglais
BACKGROUND & AIMS: Retrospective studies have found an unexpectedly high
incidence of hepatocellular carcinoma (HCC) among patients with hepatitis C virus
(HCV)-associated cirrhosis who received direct-acting antiviral (DAA) agents. We
analyzed data from the ANRS CO12 CirVir cohort to compare the incidence of HCC
in patients with cirrhosis who received DAA therapy vs patients treated with
interferon (IFN).
METHODS: Data were collected from 1270 patients with compensated biopsy-proven
HCV-associated cirrhosis recruited from 2006 through 2012 at 35 centers in France.
For descriptive purpose, patients were classified as follows: patients who received
DAA treatment (DAA group, n = 336), patients who achieved a sustained virologic
response (SVR) following an IFN-based regimen (SVR-IFN group, n = 495), or
patients who never received DAA treatment and never had an SVR following IFN
therapy (non-SVR group, n = 439). The patients were included in HCC surveillance
programs based on ultrasound examination every 6 months, and clinical and
biological data were recorded. To account for confounding by indication due to
differences in patient characteristics at treatment initiation, we constructed a time-
dependent Cox regression model weighted by the inverse probability of treatment
and censoring (IPTCW) to assess the treatment effects of DAA on time until HCC.
RESULTS: Compared with patients in the SVR-IFN group, patients in the DAA group
were older, higher proportions had diabetes or portal hypertension, and liver
function was more severely impaired. The crude 3-year cumulative incidences of
HCC were 5.9% in the DAA group, 3.1% in the SVR-IFN group, and 12.7% in the non-
SVR group (overall P < .001; unadjusted hazard ratio [HR] for HCC 2.03; 95%
confidence interval [CI] 1.07-3.84; P = .030 for the DAA group vs the SVR-IFN
group). HCC characteristics were similar among groups. Among patients with HCC,
the DAA group received less-frequent HCC screening than the other 2 groups (P =
.002). After Cox analyses weighted by the IPTCW, we found no statistically
significant increase in risk of HCC associated with DAA use (HR 0.89; 95% CI
0.46-1.73; P = .73).
CONCLUSIONS: Analysis of data from the ANRS CO12 CirVir cohort reveals that the
apparent increase in HCC incidence observed in patients with cirrhosis treated with
DAAs compared with patients who achieved SVR following an IFN therapy can be
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